dual glp 1 glucagon receptor agonists Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research The mechanisms of dual incretin
Description
Svane Maria, S
What was once a relatively small class of drugs has become one of the most significant drivers of pharmacy spend, transforming diabetes care and offering new treatment options to help address obesity
doi: 10.1016/j.ejphar.2018.03.024 [DOI] [PubMed] [Google Scholar] 237
12.9%, adjusted HR [aHR]: 0.57, 95% CI 0.51, 0.64), MACE (14.8% vs
GLP-1R is expressed in neurons of the PVN [347] that co-localize with CRH [813]
On average, patients lose about 5 pounds monthly while using semaglutide GLP-1 for weight loss, although everyone is different
